Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
Puma Biotechnology has raised $10.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2022.
Puma Biotechnology's investors include Adage Capital Management, OrbiMed, Oxford Finance LLC, T. Rowe Price, Athyrium Capital Management LP.
Puma Biotechnology is headquartered in Los Angeles, United States.
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
Puma Biotechnology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Puma Biotechnology — Funding & Investors." VCBacked, March 10, 2022, https://www.vcbacked.co/company/puma-biotechnology. Accessed September 29, 2026.
VCBacked. (2022). Puma Biotechnology — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/puma-biotechnology
{{cite web |title=Puma Biotechnology — Funding & Investors |url=https://www.vcbacked.co/company/puma-biotechnology |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated